T he human brain comprises only 2% of the body's mass, but it consumes 20% of the energy that is produced when the body is in a resting state. This high consumption of energy is crucial for the normal functioning of the brain. The energy is mostly used to reverse the ion influxes that underlie synaptic potentials and action potentials 1 (Fig. 1a) . If there is an inadequate supply of blood glucose and oxygen to a region of the brain, then neurons and glia become injured or die. This occurs in disorders such as ischaemic stroke, vasospasm after sub-arachnoid haemorrhage, the secondary ischaemia that follows spinal-cord injury, and cerebral palsy after perinatal asphyxia. To sustain neuronal function, the brain has evolved 'neurovascular coupling' mechanisms to increase the flow of blood to regions in which neurons are active, a response termed functional hyperaemia. Different information coding strategies and neural algorithms require different increases in blood flow, depending on the extent to which they consume energy. An understanding of the mechanisms that generate functional hyperaemia is a prerequisite for developing therapies to correct defects in blood flow control that occur after disorders such as stroke 2 , hypertension 3 , spinal-cord injury 4 and Alzheimer's disease 3 . Concepts of how neuronal activity controls the vascular supply of glucose and O 2 are changing rapidly. Traditionally, it was thought that active neurons generate a metabolic signal (a fall in O 2 or glucose concentration, or a rise in carbon dioxide concentration), which triggers an increase in blood flow. This idea has recently been superseded, following the discovery that neurotransmitter-mediated signalling, particularly by glutamate, has a major role in regulating cerebral blood flow, and that much of this control is mediated by astrocytes. Glutamate-mediated signalling leads to the release of nitric oxide from neurons and of arachidonic acid derivatives from astrocytes (and possibly from neurons). These molecules can either increase or decrease blood flow, depending on the local O 2 concentration, but how this switch occurs is debated. Furthermore, the relative importance of the different glutamate-released messengers varies between brain regions. Even the dogma that cerebral blood flow is controlled solely by arterioles has been challenged, with the finding that contractile cells called pericytes can control the diameter of capillaries, and that damage to these cells contributes to the long-lasting decrease in blood flow that occurs after stroke. These major conceptual shifts, which we discuss in this Review, provide a new understanding of how the brain regulates its energy supply in response to different information processing tasks. They also underpin the interpretation of data from functional imaging experiments, and offer new opportunities for developing therapeutic approaches to a range of disorders of the central nervous system.
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Neurotransmitters increase cerebral blood flow
In this Review, we focus on the control of cerebral blood flow by local neuronal activity. We pay less attention to autoregulation, which, in the face of changes in systemic blood pressure, maintains an approximately constant blood flow to the brain.
Early researchers favoured the idea that blood flow is locally controlled by a negative-feedback system in which neural activity leads to energy demand, because ATP is used to restore ion gradients after the generation of synaptic and action potentials 1 . This ATP use was thought to produce a metabolic signal that increased blood flow and therefore provided more energy (Fig. 1b) . This metabolic signal could be a lack of O 2 or glucose, or the production of CO 2 (which dilates cerebral vessels by being converted to H + after combining with H 2 O) 5 . However, manipulation of blood O 2 (refs 6, 7) and glucose 8 concentrations to test this negative-feedback hypothesis has shown that O 2 and glucose do not regulate blood flow in this way. Furthermore, during neuronal activity, the local extracellular pH initially becomes alkaline, rather than becoming acidic as would be expected if arteriolar dilation were caused by the accumulation of CO 2 . This is partly because the increase in blood flow elicited by neural activity washes CO 2 away rapidly, and partly because the neuronal Ca 2+ , H + -ATPase pump alkalinizes the extracellular space when neural activity raises the neuronal intracellular calcium concentration ([Ca 2+ ] i ) 9, 10 . These findings do not support a local CO 2 rise as the cause of the increased blood flowdespite the fact that exogenous CO 2 does increase blood flow. However, the 'metabolic messenger' adenosine (which is produced when ATP is hydrolysed) does contribute to functional hyperaemia, because blocking adenosine receptors reduces the increase in blood flow evoked by neuronal activity 11 . Furthermore, another metabolic messenger, lactate (which is produced when pyruvate production by glycolysis outstrips pyruvate consumption by oxidative phosphorylation), also increases blood flow 12 . However, as explained below (see 'O 2 modulates neurovascular signalling'), this is mediated at least partly by a modulation of neurotransmitter-induced prostaglandin signalling to blood vessels.
More recent work has shown that control of the vascular energy supply by neural activity is largely mediated by feedforward mechanisms (Fig. 1c) . In these processes, neurons either signal directly to blood vessels or activate astrocytes to release vasoactive agents onto the vessels. For both of these signalling routes, the coupling mechanisms involve neurotransmitter, particularly glutamate, signalling (Fig. 2) .
One cannot distinguish between metabolic feedback and neurotransmitter feedforward mechanisms simply by blocking neurotransmittermediated signalling. Although neurotransmitter antagonists block the increase in blood flow elicited by neural activity [13] [14] [15] [16] [17] , they also block the energy consumption evoked by synaptic signalling 1, 18, 19 . However, the roles of energy consumption and neurotransmitter-mediated signalling in regulating blood flow can be disentangled. Blocking the enzymes downstream of glutamate receptors that generate nitric oxide and arachidonic acid derivatives greatly reduces functional hyperaemia but has little effect on the energy use that is associated with neural activity 18, 20 .
Neuronal signalling to blood vessels
Synaptic release of glutamate activates neuronal NMDA (N-methyld-aspartate) receptors, resulting in Ca 2+ entry into neurons and activation of neuronal nitric oxide synthase (nNOS). This releases NO, which dilates vessels 21 , both in brain slices (which allow more refined mechanistic investigations, but lack intravascular pressure and blood flow that can release messengers that modulate the properties of vascular smooth muscle) and in vivo (Fig. 2) . In the cortex, inhibition of nNOS reduces the increase in blood flow that is associated with neural activity 22 , suggesting a role for NO in neurovascular coupling. However, the response is restored by the addition of NO donors, which provide a constant concentration of NO. This indicates that, although the presence of NO is required, a dynamic rise of NO concentration in response to neuronal activity does not directly mediate neuron-to-vessel signalling 23 . Instead, NO might be needed to modulate the pathways in astrocytes which dilate and constrict blood vessels (see 'NO modulates astrocyte signalling'). In the cerebellum, by contrast, NO donors do not reverse the reduction in functional hyperaemia caused by inhibiting nNOS, demonstrating that NO directly mediates a component of the response 24, 25 . The activation of peptidergic interneurons can also dilate or constrict vessels in the cortex 26 , but the dilations that have been observed were usually irreversible (within the 7-min recording period). In addition, it is unclear whether these effects involve peptide release and whether they reflect direct signalling from neurons to vessels or indirect signalling by way of astrocytes (see ' Astrocyte signalling to blood vessels'). Finally, the neurotransmitter GABA (γ-aminobutyric acid), acting through GABA A receptors, also mediates a component of the vasodilation produced in the cortex by basal forebrain stimulation 27 , but it is unclear whether this is a direct effect on the vasculature or is mediated by an effect on neurons or astrocytes.
Astrocyte signalling to blood vessels
Astrocytes are ideally situated to function as relay cells in neurovascular communication, as was suggested more than a century ago by Ramón y Cajal. They surround synapses and thus can be stimulated by neuronal activity, whereas their endfoot processes envelop blood vessels and can signal to the smooth muscle cells that control vessel diameter.
In theory, astrocytes can increase blood flow in response to neuronal activity by releasing potassium ions from their endfeet apposed to arterioles, because modest increases in extracellular K + concentration (up to ~10 mM [ Figure 1 | Energy supply, usage and blood flow regulation in the brain. a, ATP is generated from glycolysis and mitochondrial oxidative phosphorylation in neurons and glia. ATP is mainly consumed (red arrows) by ion pumping in neurons, to maintain the ion gradients underlying synaptic and action potentials, following Na + entry (blue arrows) through ionotropic glutamate receptors (iGluR) and voltage-gated Na + channels (NaV). It is also used in glia for Na + -coupled neurotransmitter uptake by excitatory amino acid transporters (EAAT) and for metabolic processing (shown for conversion of glutamate to glutamine), and on maintaining the cells' resting potentials. b, The negative-feedback control hypothesis for vascular energy supply, in which a fall in energy level induces an increased cerebral blood flow (CBF). c, The feedforward regulation hypothesis for vascular energy supply. (BK) channels in astrocyte endfeet, releasing K + onto vessels. A caveat is that these experiments used a thromboxane analogue to maintain vessel tone in the brain slices studied, and this analogue has been shown to stimulate the trafficking of BK channels to the surface membrane of astrocytes 33 . It remains to be determined whether this K + release mechanism contributes to the regulation of blood flow in vivo.
There is strong evidence from brain slice and isolated retina preparations that astrocytes can control blood flow through the production and release of metabolites of arachidonic acid. When glutamate released from neurons activates astrocyte mGluRs (Fig. 2) , the resultant rise in [Ca 2+ ] i activates phospholipase A 2 , evoking the production of arachidonic acid from membrane phospholipids. The build-up of arachidonic acid leads, in turn, to the production of its metabolites, including prostaglandins and epoxyeicosatrienoic acids (EETs), which dilate nearby arterioles 15, [34] [35] [36] [37] . The prostaglandin involved is often suggested to be PGE 2 , although many studies rely on inhibiting only the first enzyme (cyclooxygenase) in the prostaglandin-synthesis pathway, and other prostaglandins may contribute to the dilation. (The main pathways by which arachidonic acid derivatives are produced are shown in Fig. 3 . This is mediated 34 by the conversion of arachidonic acid to 20-hydroxy-eicosatetraenoic acid (20-HETE), probably by the enzyme CYP4A in vascular smooth muscle cells (Fig. 2) , mediated by a phospholipase A 2 derivative (presumably 20-HETE), during cortical spreading depression -a pathological wave of cell depolarization and refractoriness lasting minutes, after a brief period of increased excitability, which spreads across the cortex.
Modulation of these arachidonic acid metabolic pathways for therapeutic effect will depend on understanding the isoforms of the enzymes that synthesize the vasoactive messengers. For example, prostaglandins that mediate physiological vasodilation in response to a rise in astrocyte [Ca 2+ ] i are mainly produced by cyclooxygenase 1 (COX1) 43 , which is ] i rise or prostaglandin release, and still occurred when glutamate receptors were blocked. In a related study in the visual cortex, blocking glutamate uptake prevented astrocyte [Ca 2+ ] i increases and light-reflectance changes that are attributed to increased blood flow 51 . However, interpretation of these data is complicated because, first, blood flow was not measured directly, second, it was unclear whether the astrocyte [Ca 2+ ] i rises were generated by mGluRs or by glutamate uptake, and third, blocking uptake will raise the extracellular glutamate concentration, which could desensitize glutamate receptors and have indirect effects. Similarly, in the olfactory bulb, co-transport of Na + with GABA taken up into astrocytes raises , presumably by releasing arachidonic acid to generate 20-HETE ( Fig. 2) , although this was not tested.
The importance of astrocytes versus neurons
The relative importance of the neuronal and astrocytic vasodilating pathways remains a matter of debate, because synaptic glutamate release raises [Ca 2+ ] i in both cell types . Blood flow responses are strongly correlated with local field potentials that reflect synaptic and action potentials in neurons 55, 56 , and ionotropic glutamate receptor antagonists significantly decrease both field potentials and blood flow responses to stimulation in the cerebellum, cortex and olfactory bulb 16, 17, 55 . This might indicate that a rise of [Ca 2+ ] i in neuronal dendrites initiates much of the increase in blood flow 53 . However, the glutamate release that generates field potentials also activates astrocyte mGluRs, so field-potential amplitudes will also be correlated with astrocyte receptor activation.
A correlation of blood flow changes with field potentials is therefore not sufficient to prove that postsynaptic neuronal signalling dominates the control of blood flow. Furthermore, experiments blocking ionotropic glutamate receptors to prevent the release of neuronal messengers will decrease neuronal firing, inhibiting glutamate release onto astrocytes and thus preventing the release of astrocyte messengers. The potential for astrocytes to control blood flow is demonstrated by the fact that neural activity raises [Ca 2+ ] in astrocytes 54, 57 , and that uncaging of Ca 2+ in astrocytes dilates or constricts arterioles 34, 35, 43, 44 . If the simplified scheme shown in Fig. 2 were correct, then the relative contributions of neuronal and glial signalling could be dissected by blocking either the neuronal NO pathway or the astrocyte arachidonic acid pathways. Knocking out or blocking nNOS (the only form of NOS contributing to functional hyperaemia 22 ) does not affect whiskerstimulation-induced neural field potentials, but reduces the resulting blood flow increases by 37-60% in the somatosensory cortex 22, 58 . In the cerebellum, knockout or inhibition of nNOS decreases activity-induced blood flow by 50-90% 13, 24, 25, 59 . The remaining blood flow increase may be mediated by adenosine 14 or K + (ref. 60 ), but the possible contribution of prostaglandins and EETs has not been investigated. Blocking prostaglandin production with cyclooxygenase inhibitors reduces functional hyperaemia in the cortex 61, 62 by 48-60% without affecting neuronal field potentials, whereas blocking EET production inhibits the response by 35-70%
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. Thus, NO, cyclooxygenase and epoxygenase products are all important for generating functional hyperaemia in the cortex, whereas NO is more dominant in the cerebellum 59 . However, we will see below (see 'NO modulates astrocyte signalling') that the different pathways interact at the level of the enzymes producing arachidonic acid derivatives. In addition, a saturating interaction at the level of the arteriole smooth muscle membrane potential is expected if EETs and prostaglandins both dilate arterioles by opening K + channels, because once one pathway has hyperpolarized the cell out of the activation range of voltage-gated Ca 2+ channels, then further opening of K + channels will have no effect. Caution is therefore needed in interpreting the results of experiments in which single enzymes are blocked.
Pathway-specific signalling differences
Even if functional hyperaemia is largely driven by synaptic glutamate release, it does not follow that all excitatory synapses are equally influential in controlling blood flow, even if they impinge on cells in the same , monotonically increasing with activity for the transcallosal pathway and showing a maximum at an intermediate level of input for the thalamocortical input. These differences may be partly due to differential activation of interneurons that release vasoactive peptides 56 . However, they may also reflect differences in the functional anatomy of neuro-vascular coupling for the two input pathways. For example, some of the 8,000 synapses innervating a typical rodent neocortical pyramidal cell 1 will release NO closer to arterioles, or induce a [Ca 2+ ] i rise in astrocytes that is more effective at releasing vasodilatory messengers onto arterioles, than will other synapses. Similarly, in the cerebellar cortex, although cerebral blood flow increases evoked by activation of the parallel and climbing fibre inputs to Purkinje cells depend partly on NO, the blood flow response to parallel fibre stimulation also involves a rise in [K + ] o , whereas the response to climbing fibre activation partly involves adenosine release 60, 63 . Thus, the relative importance of the neuronal and astrocyte pathways is likely to differ across brain areas, and even between different neural pathways in the same area. Consequently, the dependence of blood flow increases on the underlying neural activity will differ between different pathways, implying that functional imaging signals arising from these pathways will also reflect different aspects of neuronal function (see 'What does functional imaging measure?'). Similarly, therapeutic modulation of the signalling pathways controlling cerebral blood flow may have different effects in different brain areas, and on different neuronal pathways in the same area.
NO modulates astrocyte signalling
Assessing the relative significance of, or interfering therapeutically with, the different signalling pathways producing functional hyperaemia is complicated by interactions between them. The effects of the NO, cyclooxygenase and epoxygenase pathways can occlude each other. In the cortex, for example, functional hyperaemia is inhibited ~50% by blocking NOS and ~50% by blocking cyclooxygenase, but blocking both produces only a 70% inhibition 62 . Similarly, blocking NOS, blocking EET production, or blocking both pathways together all produce a ~60% inhibition of functional hyperaemia 37 . These results may be explained by interactions between the NO and arachidonic acid pathways, which are shown in Fig. 4 .
Nitric oxide inhibits the enzymes that synthesize 20-HETE and EETs 64 . It also, much more weakly, inhibits prostaglandin production by COX2, but stimulates COX1 (ref. 65) . The inhibition of the synthesis of the vasoconstrictor 20-HETE by NO is of particular interest for two reasons. First, this effect may underlie a significant fraction of the dilating effect of NO 66 (20-60% in different vessels 64 ), which is independent of the NO vasodilation mediated by cyclic GMP (Fig. 4) . Second, it provides a probable explanation for why, in the neocortex, NO is required for functional hyperaemia to occur, but is not the primary mediator of the increase in blood flow 23 . If the main cause of the blood flow increase is the generation of arachidonic acid by astrocytes, then having NO present to inhibit 20-HETE formation will ensure that only the vasodilatory prostaglandin and EET derivatives of the arachidonic acid will affect arteriole diameter. In the retina, however, where arteriole vasodilations are produced by EETs 34 , the presence of NO promotes light-induced constrictions and inhibits dilations, suggesting that the production of EETs is more NO sensitive than is the production of 20-HETE 34 .
O 2 modulates neurovascular signalling
Variations in O 2 concentration in brain tissue alter neurovascular coupling in two ways. The O 2 level affects the synthesis of the glial and neuronal messengers involved, and also alters the levels of lactate and adenosine that modulate the pathways by which these messengers . NO also weakly stimulates COX1 and inhibits COX2 (not shown) 65 . Endothelial nitric oxide synthase (eNOS) can be activated by flow-induced shear stress or by acetylcholine (ACh). Other abbreviations as in earlier figures. ] i led to arteriolar constriction, whereas with a physiological [O 2 ], vasodilation occurred. These changes are, in part, predicted from the modulatory effects of O 2 and NO on the signalling pathways outlined above (in this and the preceding section). The suppression of 20-HETE formation by the lower O 2 concentration is expected to reduce the vasoconstriction produced when arachidonic acid is generated in astrocytes (Fig. 5) , and the lower [O 2 ] will also result in less NO being present to inhibit the formation of vasodilatory EETs (Fig. 4) in tissues where these contribute to dilation.
However, two other factors were also shown to contribute significantly to the effects of lowering [O 2 ] (ref. 35; Fig. 6 ). As O 2 concentrations decrease, the lack of energy for ATP synthesis causes an increase in the level of extracellular adenosine (Fig. 6 ), which binds to adenosine A 2A receptors on vascular smooth muscle cells to depress vessel constriction. In addition, a decrease in the rate of oxidative phosphorylation relative to the rate of glycolysis results in lactate production (Fig. 6) . Monocarboxylate transporters release the lactate into the extracellular space, where it reduces the clearance of extracellular PGE 2 by the prostaglandin transporter (Fig. 6) . Thus, when PGE 2 is released from astrocytes, extracellular PGE 2 increases to a greater degree, resulting in larger arteriole dilations 35 . This effect of lactate may partly explain why, in humans and rats in vivo, cerebral blood flow is regulated by the lactate/pyruvate concentration ratio and thus by the NADH/NAD + ratio 12 . Interestingly, lactate is released into the extracellular space during synaptic activity 71 , which should promote vasodilation. Despite our understanding of how O 2 levels regulate astrocyte-mediated neurovascular coupling in brain slices 
Control of blood flow at the capillary level
Until recently, it was assumed that neurovascular coupling is mediated solely by changes in the tone of the smooth muscle that forms a continuous layer around arterioles. This idea has been challenged by Review insight the discovery that pericytes -cells present at ~50-μm intervals along capillaries -can markedly alter capillary diameter, and thus potentially regulate cerebral blood flow at the capillary level.
Pericytes express contractile proteins, and their location on capillaries led to the suggestion, some 130 years ago, that they could constrict the microvasculature 72 . This idea was reinforced with observations that substances that alter arteriole diameter, including arachidonic acid derivatives and neurotransmitters, can contract and relax pericytes cultured on rubber membranes 73 . Importantly, in a series of papers, pericytes on isolated retinal capillaries were demonstrated to constrict or dilate in response to neurotransmitters, as a result of [Ca 2+ ] i alterations 74 . It is assumed that the signalling pathways controlling pericyte constriction and dilation will be similar to those for arterioles shown in Fig. 2 , but this still needs to be tested. In situ in brain slices, pericytes constrict in response to noradrenaline and dilate in response to glutamate 75 , and in the isolated retina, blocking ionotropic GABA receptors constricts capillaries, demonstrating that endogenous transmitter release can regulate capillary diameter 75 . Regulation of cerebral blood flow at the capillary level has yet to be demonstrated in vivo in physiological conditions 72 , although it does occur after ischaemia 76 . Signals for contraction (presumed to be depolarization) and perhaps for dilation (hyperpolarization) can propagate from one pericyte to another 74, 75 . This signal spread may occur through gap junctions between the interdigitating processes of the pericytes themselves, or through gap junctions with endothelial cells. Because active neurons are, on average, closer to pericytes than to arterioles 77 (8-23 μm away versus 70-160 μm), this signal spread raises the theoretical possibility that vascular responses to changes in neuronal activity may be initiated by pericytes and then propagated to upstream arterioles.
The importance of capillary diameter control by pericytes for regulating cerebral blood flow will depend on the fraction of the haemodynamic resistance of the vascular network that the capillaries contribute. 78, 79 suggest that the capillary resistance is between 16% and 70% of the total vascular resistance (arterioles plus capillaries plus venules) within the brain parenchyma. If blood flow in capillaries obeys Poiseuille's law of fluid dynamics (see below), with flow proportional to the fourth power of the vessel diameter, then these values lead to the conclusion that a 2.1-fold capillary dilation produced by superfused glutamate in the presence of noradrenaline 75 could, in principle, increase blood flow 1.18-to 2.98-fold 72 , and thus contribute significantly to functional hyperaemia. However, this may overestimate the role of pericytes if endogenous noradrenaline release is less than that applied when probing the effect of glutamate 75 , or if the effect of superfused glutamate in brain slices overestimates dilations produced in perfused vessels in vivo by neurons releasing glutamate. On the other hand, Poiseuille's law severely underestimates the power of pericytes to regulate blood flow, because red and white blood cells have to deform considerably to pass through capillaries that constrict below ~5 μm -or they may not be able to pass through at all, which becomes important when pericytes constrict capillaries after ischaemia 76 . This will result in a more non-linear dependence of flow on diameter, enhancing the influence of capillaries on blood flow. Experiments are needed to define the importance of pericytes for regulating blood flow in vivo.
Models in the literature

Blood flow rises more than energy use
Traditional analyses of sensory systems assumed that external stimuli induce action potentials in neurons with receptive fields 'tuned' to particular features of the stimuli. On this basis, low levels of spontaneous neuronal activity merely provide a 'noise' background against which the stimulus must be detected, and sensory input should greatly increase neuronal activity and hence cortical energy use. Recently, however, it has been suggested that incoming sensory information produces only small changes to the ongoing activity level in cortical neurons 80 . Indeed, across a range of sensory systems, less than a 10% change of neuronal 
Review insight
spiking is produced by perceptual tasks used in functional imaging experiments 81 , and as a result sensory input alters cortical energy use by a relatively small fraction 82 . The fractional increase in blood flow induced by sustained neuronal activity is at least 4-fold greater than the increase in ATP consumption by the neurons 82 . This is consistent with blood flow being mainly regulated by feedforward neurotransmitter-mediated mechanisms rather than by a negative-feedback loop driven by energy demand (Fig. 1b, c) , because a negative-feedback system could not produce a sustained increase in energy supply that is larger than the increase in energy consumption. As explained below (see 'What does functional imaging measure?'), this disproportionate increase in blood flow is the basis of the blood-oxygenlevel dependent (BOLD) functional imaging technique. It was initially thought that most of the energy used when neurons are activated came from glycolysis rather than oxidative phosphorylation, because neuronal activity increases glucose uptake much more than O 2 uptake 83 . However, later studies found less of a difference in the glucose and O 2 uptake rates 84 , and far more ATP is produced by oxidative phosphorylation than by glycolysis per glucose molecule. As a result, even with a much smaller increase in O 2 uptake than in glucose uptake 83 , at least 60% of the extra ATP production would be occurring by oxidative phosphorylation 85 , and more recent work suggests that almost all of the ATP is generated by oxidative metabolism of glucose 82 . A possible explanation for the large increase in blood flow induced by activity, relative to the increase in O 2 uptake and ATP production, was based on modelling of O 2 uptake: a large increase in blood flow (driven by glutamate release, not by O 2 deficit) may be needed to generate even a small increase in O 2 uptake 86 . However, pharmacologically blocking most of the increase in blood flow produced by activity has little effect on the increase in O 2 consumption 87 , arguing against this explanation. At present, therefore, it seems that a large increase in blood flow (and glucose uptake) should not be needed to maintain energy supply during normal brain activity. Perhaps this large increase occurs as a by-product of a system that attempts to maintain blood flow during conditions of greater energy need that can occur pathologically (see 'Spreading depression and neurovascular coupling').
What does functional imaging measure?
BOLD functional magnetic resonance imaging (fMRI) of brain activity depends crucially on functional hyperaemia 88 . This technique detects a magnetic resonance radio signal emitted from proton spins. The strength of the signal is decreased by deoxyhaemoglobin, which is paramagnetic and makes the magnetic field less uniform. Without functional hyperaemia, the O 2 consumption powering neuronal activity would increase the deoxyhaemoglobin level and thus decrease the MRI signal. In fact, BOLD images show an increase in intensity in active brain areas. This is because the increase in blood flow evoked by neuronal activity brings in excess oxygenated blood, so that the deoxyhaemoglobin level falls and the MRI signal is increased. Thus, simplistically, the size of the BOLD fMRI signal is determined by the difference between the amount of functional hyperaemia, which increases the signal, and the use of O 2 by neurons, which reduces the signal (there is also a dependence on blood volume, which increases with the pressure increase driving the increased flow, which is ignored for simplicity here).
Because the effect of functional hyperaemia dominates, it follows that, to a large extent, BOLD fMRI signals reflect the causes of functional hyperaemia. When it was thought that activity-evoked blood flow increases were driven by energy use, fMRI images were believed to reflect energy use by active neurons. The discovery that functional hyperaemia is driven largely by glutamate release indicates, instead, that fMRI mainly images the neurovascular signalling consequences of synaptic activity 89 . Consistent with this, cortical BOLD signals correlate slightly better with field potentials reflecting stimulus-evoked synaptic currents than with stimulus-evoked action potentials 90 , but they still correlate well with action potential activity 90 because cortical synaptic potentials are themselves well correlated with pyramidal cell spiking.
It would be instructive to repeat this experiment in the cerebellum, where parallel fibre activity leads to a glutamate-mediated increase in blood flow, but to a decrease in principal (Purkinje) cell firing due to disynaptic inhibition 55 . Because BOLD signals mainly reflect the causes of functional hyperaemia, if we assume that this is largely produced by astrocyte signalling, BOLD fMRI images will essentially reflect the activation of astrocyte mGluRs (Fig. 2) . Conversely, if the neuronal NO pathway dominates, then BOLD essentially images the activation of postsynaptic nNOS. But BOLD may still give information on neuronal spiking activity, for two reasons. First, glial [Ca 2+ ] i increases (and downstream generation of arachidonic acid derivatives) can be closely correlated with the activity of adjacent neurons 51 , presumably because the glia respond to glutamate released at synapses onto the neurons. Second, typical voxel sizes used in fMRI (~1.5-3 mm) include many output synapses from the local axon collaterals of pyramidal cells in the cortex 91 , and so the BOLD signal obtained, although originating from functional hyperaemia evoked by glutamate release, could nevertheless reflect the local pyramidal cell spiking activity that drives glutamate release at those synapses. For this to be the case, the effect on the vasculature of the axon collateral synapses would have to outweigh the effect of synapses carrying input to that part of the cortex from other brain areas.
The spatial resolution of BOLD fMRI has increased with the field strength used for imaging, and now approaches 200 μm in animals 85 . Even higher resolution can be obtained by optical imaging of changes in the oxy-and deoxyhaemoglobin concentrations within vessels 92 . The different spatial ranges of the vasodilatory mechanisms outlined in Fig. 2 , that is, the distance that NO 93 or arachidonic acid derivatives can diffuse and the distance that [Ca 2+ ] i increases propagate through astrocytes, will limit the spatial resolution that functional imaging can potentially attain.
Spreading depression and neurovascular coupling
Functional hyperaemia could be particularly important for preventing neuronal death in pathological conditions in which energy use is raised, but it is in precisely these conditions that neurovascular coupling sometimes fails. One example is in cortical spreading depression, which occurs in migraine 94 , when it is relatively benign, and repeatedly after stroke, subarachnoid haemorrhage or brain trauma, when it is associated with delayed neurological deficits [95] [96] [97] . Spreading depression is associated with a notable failure of brain ion homeostasis 98 . The extracellular potassium concentration rises transiently from ~3 to ~50 mM, depolarizing neurons and astrocytes, and the extracellular glutamate concentration rises 99 as a result of release from neurons and impairment of uptake 100 . Brain energy use increases 101 , presumably because the increase in glutamate concentration activates an influx of Na + and Ca 2+ ions that need to be pumped out, and the sodium pump is further activated by the rise in [K + ] o . As a result, the cortex consumes more O 2 and glucose than is provided by the blood, resulting in a decrease in their extracellular concentrations [101] [102] [103] . This increase in energy use is pronounced during the first few minutes of spreading depression, but persists at a lower level for hours 101 . A failure of neurovascular coupling to provide a sufficient increase in blood flow during the increased energy consumption generated by spreading depression may underlie the neurological deficits associated with spreading depression after subarachnoid haemorrhage 97 . During spreading depression, cerebral blood flow is initially transiently increased 101, 102 (less so in migraine than in stroke or brain trauma 94, 104 ), sometimes with a preceding decrease in blood flow 46, 105 . After a few minutes, however, blood flow is reduced 94, 101, 102, 105 by 20-30%. This decrease lasts for hours despite the increase in energy consumption during this period Review insight flow induced by spreading depression 104, 106 . CGRP may act on receptors on smooth muscle cells or on astrocytes to produce this effect, although blocking the production of prostaglandins or EETs does not reduce the blood flow increase 104 , indicating that a direct action on smooth muscle is more likely. Release of NO has also been suggested to contribute to the vasodilation 105, 106 , although this is controversial 104 and the effects of NOS blockers may reflect a need for NO to be present to suppress vasoconstriction mediated by 20-HETE (Fig. 4) .
The sustained decrease in blood flow caused by spreading depression may be partly mediated by 20-HETE generated from astrocyte arachidonic acid. Reducing the increase in astrocyte [Ca 2+ ] i that accompanies spreading depression (using thapsigargin to prevent Ca 2+ accumulation in internal stores), or blocking phospholipase A 2 to prevent arachidonic acid formation, both prevented the vasoconstriction 46 . This study, however, imaged only the early vasoconstriction occurring before the transient increase of blood flow, and not the long-lasting constriction that reduces blood flow for hours. During the prolonged constriction, normal functional hyperaemia is disrupted: vessels no longer dilate to physiological activation 107 . This is partly due to an impairment of the NO system 105, 108 , which normally dilates vessels directly or suppresses 20-HETE-mediated constrictions (Fig. 4) , and may reflect the fall in O 2 concentration from ~24 to ~12 μM during this period 101 , which will approximately halve NO production (Fig. 5) . Indeed, more generally, the fact that O 2 supply by the blood depends partly on the release of the vasodilator NO, which requires O 2 for its formation, suggests a potentially damaging feedback loop. An increase in energy consumption lowers the O 2 concentration 101 , which decreases NO formation, lowering blood flow and reducing the O 2 concentration further.
Neurovascular coupling after ischaemia
Following brain ischaemia, when an occluding intraluminal thrombus is cleared from a blood vessel either spontaneously or therapeutically using exogenous tissue plasminogen activator (tPA), after a brief period of hyperaemia there is a decrease in blood flow lasting several hours 2, [109] [110] [111] . This inadequate matching of blood flow to neural activity may produce damage to neurons or glial cells beyond that caused by the initial ischaemia. The decreased flow, or 'no-reflow phenomenon' , was attributed to a reduction in capillary diameter as a result of astrocyte endfoot swelling, causing capillary blockage by blood cells and fibrin 109 , but later work suggested that this effect had been overestimated 112 . A failure of arteriole vasodilation mechanisms (tested with CO 2 and acetylcholine, which both release NO 113 and arachidonic acid derivatives 114 ) may underlie the long-lasting decrease in blood flow 2, 110, 115 . However, in studies measuring blood flow and not vessel diameter, defects in arteriole dilation would be hard to distinguish from a situation in which arteriole dilation occurs but fails to increase blood flow because some capillaries are blocked.
Recent evidence indicates an important role for capillary pericytes in the long-lasting blood flow decrease following ischaemia. Some pericytes constrict at the start of ischaemia 75 . This may be because their [Ca 2+ ] i rises in the absence of ATP to pump Ca 2+ out of the cell, although altered release of vasoactive messengers may also contribute (see below). Indeed, a decreased capillary diameter has been noted after ischaemia 111 . Interestingly, pericytes are also highly susceptible to damage in ischaemia 76 , when ATP levels are expected to be low. This raises the possibility that pericytes constrict capillaries at the start of a stroke, and then stay in rigor (because no ATP is available to relax their contractile filaments), causing the capillaries to remain too small for the passage of red blood cells. In agreement with this, pericytes remain constricted and prevent red blood cell passage even two hours after re-opening an occluded parent artery 76 . Suppression of oxidative and nitrosative stress prevents this pericyte constriction, restores the patency of capillaries, and improves tissue recovery 76 . The involvement of oxidative or nitrosative stress suggests another mechanism by which pericytes might constrict. Peroxynitrite inhibits the formation of vasodilating prostacyclin by endothelial cells 116 , resulting in the accumulation of vasoconstricting PGH 2 (Fig. 3) , and may also inhibit the formation of vasodilatory EETs 117 and NO 118 , any of which could lead to pericyte constriction.
The therapeutic use of tPA may itself alter neurovascular coupling, in part because it may extravasate and gain access to the brain parenchyma when the blood-brain barrier becomes leaky in ischaemia (a process that may be enhanced by tPA upregulating 119 matrix metalloprotease 9). There is debate about whether tPA is neurotoxic 119 , but endogenous tPA, which is released from neurons, cleaves the NR1 subunit of NMDA receptors and thus enhances NMDA receptor signalling 120 . Independent of this effect, endogenous tPA is essential for neurovascular coupling mediated by NMDA receptors and NO, because it regulates the phosphorylation of nNOS and thereby promotes NO release 121 . Accordingly, exogenous tPA promotes vessel dilation in an NO-dependent manner 122 , but it also enhances the failure of vasodilation that occurs after stroke 123 .
To complicate the interpretation of these data, when used clinically tPA is co-packaged with a vehicle, a high concentration of l-arginine, which will promote NO formation by NOS. This will contribute to vasodilation and could possibly damage neurons.
Neurovascular coupling in Alzheimer's disease
There is increasing evidence for vascular factors having a causal role in the development of Alzheimer's disease 3 . Many patients with Alzheimer's disease have regional cerebral hypoperfusion 124 , which correlates with cognitive decline 125 . Amyloid-β peptide decreases functional hyperaemia by promoting oxidative stress 126 , which inhibits the production of astrocytic and neuronal vasodilating messengers [116] [117] [118] waves in the astrocytes of mice with amyloid-β plaques 127 , together with increased contractility of vascular smooth muscle cells 128 , will also disrupt the normal regulation of cerebral blood vessels by astrocytes and neurons. Such changes in neurovascular coupling may make it hard to interpret BOLD fMRI signals from older subjects 129 , just as inhibiting neurovascular coupling pharmacologically alters the relationship between neuronal activity and BOLD signals 20 . Similarly, the formation of an astrocytic scar after traumatic brain injury is likely to profoundly alter neurovascular coupling.
Prospects for new therapies
There have been four major conceptual shifts in our understanding of how cerebral blood flow is regulated. It is now thought that neurotransmitters, particularly glutamate, rather than energy use are the principal agents generating activity-induced blood flow; that astrocytes mediate a large part of this blood flow control; that O 2 concentration regulates the relative importance of the signalling pathways involved; and that control of blood flow occurs at the capillary level as well as the arteriole level. These developments not only provide an increased understanding of how neural computation is powered, they also offer opportunities for developing therapies for treating disorders of cerebral blood flow.
In general, identifying the signalling pathways that regulate cerebral blood flow provides opportunities for manipulating those pathways therapeutically. This is conceptually straightforward for neurotransmitter-mediated signalling pathways that depend on well understood receptors and enzymes that can, in principle, be blocked. This could be done, for example, at the level of astrocyte mGluRs or the enzymes that generate vasoactive messengers such as cyclooxygenase, epoxygenase, CYP4A or NOS. The existence of many pathways regulating blood flow (Fig. 2) may allow subtle therapeutic modification of blood flow in different conditions or brain areas, so long as interactions between the different pathways (Fig. 4) are taken into account. The advent of new imaging techniques for rapid assessment of patients' cerebral blood flow could also enable therapies to be given earlier, before neuronal damage has been initiated. In particular, the signalling changes that occur in spreading depression and stroke suggest new therapeutic approaches, as follows.
The decrease in blood flow that follows spreading depression 101, 102, 105 , which may contribute to cognitive decline after brain trauma, stroke 97 , may be produced by excessive generation of vasoconstricting 20-HETE formed from astrocyte arachidonic acid. This could be tested using inhibitors of the CYP4A enzyme that generates 20-HETE. A role for pericyte constriction in this phenomenon should also be tested.
The long-lasting decrease in blood flow observed after experimental ischaemia 2, [109] [110] [111] , produced in part by pericyte constriction 75, 76 , indicates that even rapid dissolution of a clot using tPA may be limited in its effects on restoring perfusion. This suggests that, in combination with tPA application, it would be worth trying to preserve normal pericyte function. Pericyte constriction and death after ischaemia are mediated by oxidative or nitrosative stress 76 , so infusing antioxidants at the same time as tPA may be a useful adjuvant approach. Preclinical studies assessing how pericyte properties vary with age and gender, and whether pericyte contraction contributes to pathology in hypertension (which is associated with neurovascular dysfunction
